Topoisomerase II alpha expression and the benefit of adjuvant chemotherapy for postoperative patients with non-small cell lung cancer

Table 3 Comparison of DFS among different chemotherapy groups in patients with low TopIIα expression

Chemotherapy regimens		Number	Median DFS (months)	P
Vinorelbine	Containing	29	48.16	0.065
	Not containing	88	16.23
Gemcitabine	Containing	39	14.13	0.530
	Not containing	78	22.74
Docetaxel	Containing	33	15.74	0.194
	Not containing	84	22.74
Paclitaxel	Containing	16	22.97	0.990
	Not containing	101	18.76

ISSN: 1471-2407